NCT00006200Unknown2 期
Thalidomide and Dacarbazine for Metastatic Melanoma
National Center for Research Resources (NCRR)1 个研究点 分布在 1 个国家开始时间: 2000年9月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 试验地点
- 1
研究概览
简要总结
The purpose of this clinical trial is to assess the activity of thalidomide in combination with dacarbazine (DTIC) in patients with metastatic melanoma. Safety and toxicity of the two drugs will also be assessed. Dacarbazine is the standard medical treatment for metastatic melanoma. It has been shown to produce tumor shrinkage in approximately 20% of patients with advanced melanoma. This shrinkage is usually incomplete and lasts a short time. Thalidomide is a drug that inhibits tumor blood vessel growth. It can be given orally. It is hoped that this combination can be given to patients with metastatic melanoma without causing too much toxicity while increasing the response rate.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic melanoma.
- •Lesions must be measurable.
- •Patient must have the following minimum labs: ANC> 1500/mm3, Hemoglobin > 8 mg/dl; platelets > 100,000 mm3; and liver function tests < 5x normal; and creatinine < 1.5 mg/dl.
- •ECOG performance status >
- •No prior therapy with DTIC or thalidomide
- •No other history of malignancy other than curatively resected basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- •Patients must not be pregnant or lactating.
- •Sexually active men and women of childbearing age must use adequate contraception. All patients must understand the potential for severe birth defects with thalidomide and must be able to follow instructions to avoid conception while taking thalidomide
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryMelanoma (Skin)NCT00104988SWOG Cancer Research Network64
Unknown
2 期
Dabrafenib + Trametinib + PDR001 In Colorectal CancerMetastatic Colorectal CancerNCT03668431Massachusetts General Hospital25
招募中
2 期
Cadonilimab Plus Anlotinib for R/M/P Cervical CancerCervical CancerNCT05817214Zhongnan Hospital35
已完成
2 期
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic MelanomaNeoplasm MetastasisMelanomaNCT00001832National Cancer Institute (NCI)170
已完成
2 期
Thalidomide-Dexamethasone for Multiple MyelomaMultiple MyelomaNCT00038090M.D. Anderson Cancer Center83